Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Lancet Oncol
    January 2018
  1. MALAGA G, Cuba-Fuentes S, Romero-Albino Z
    Implementation of a community-based breast cancer management programme.
    Lancet Oncol. 2018;19:e3.
    >> Share

    December 2017
  2. BURKI TK
    Improved progression-free survival in metastatic breast cancer.
    Lancet Oncol. 2017 Dec 21. pii: S1470-2045(17)30952.
    >> Share

  3. NELSON R
    San Antonio Breast Cancer Symposium 2017.
    Lancet Oncol. 2017 Dec 14. pii: S1470-2045(17)30930.
    >> Share

  4. DERKS MGM, van de Velde CJH
    Neoadjuvant chemotherapy in breast cancer: more than just downsizing.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30914.
    >> Share


  5. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30777.
    >> Share

  6. SALGADO R, Loi S
    Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30905.
    >> Share

  7. DENKERT C, von Minckwitz G, Darb-Esfahani S, Lederer B, et al
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30904.
    >> Share

  8. DI LEO A, Johnston S, Lee KS, Ciruelos E, et al
    Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Dec 6. pii: S1470-2045(17)30688.
    >> Share

  9. HO AY, Hu ZI, Mehrara BJ, Wilkins EG, et al
    Radiotherapy in the setting of breast reconstruction: types, techniques, and timing.
    Lancet Oncol. 2017;18:e742-e753.
    >> Share

    November 2017
  10. HURVITZ SA, Martin M, Symmans WF, Jung KH, et al
    Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2017 Nov 23. pii: S1470-2045(17)30716.
    >> Share

  11. COLLEONI M, Luo W, Karlsson P, Chirgwin J, et al
    Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 17. pii: S1470-2045(17)30715.
    >> Share

  12. MARTIN M, Holmes FA, Ejlertsen B, Delaloge S, et al
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30717.
    >> Share

  13. CHAVEZ-MACGREGOR M, Mittendorf EA
    Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30844.
    >> Share

  14. GOURD E
    Thermography should not be used in breast cancer screening.
    Lancet Oncol. 2017 Nov 2. pii: S1470-2045(17)30833.
    >> Share

    October 2017
  15. COSTA L, Ferreira AR
    Adjuvant zoledronic acid to treat breast cancer: not for all.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30695.
    >> Share

  16. COLEMAN R, Hall A, Albanell J, Hanby A, et al
    Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30603.
    >> Share

  17. GOURD E
    Insulin analog linked to breast cancer risk.
    Lancet Oncol. 2017 Oct 5. pii: S1470-2045(17)30772.
    >> Share

  18. DUGGAN C, Dvaladze AL, Tsu V, Jeronimo J, et al
    Resource-stratified implementation of a community-based breast cancer management programme in Peru.
    Lancet Oncol. 2017;18:e607-e617.
    >> Share

  19. PINEROS M, Ramos W, Antoni S, Abriata G, et al
    Cancer patterns, trends, and transitions in Peru: a regional perspective.
    Lancet Oncol. 2017;18:e573-e586.
    >> Share

    September 2017
  20. GOURD E
    Pyrotinib shows activity in metastatic breast cancer.
    Lancet Oncol. 2017 Sep 21. pii: S1470-2045(17)30755.
    >> Share

  21. EICHBAUM MHR, Kissel N, Neunhoeffer T, Dollas L, et al
    Hypoglossal paresis caused by a solitary breast cancer metasasis at the basal skull.
    Lancet Oncol. 2017;18:e552.
    >> Share

    August 2017
  22. DELALOGE S, DeForceville L
    Targeting PI3K/AKT pathway in triple-negative breast cancer.
    Lancet Oncol. 2017 Aug 8. pii: S1470-2045(17)30514.
    >> Share

  23. KIM SB, Dent R, Im SA, Espie M, et al
    Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2017 Aug 8. pii: S1470-2045(17)30450.
    >> Share

  24. KERR J, Anderson C, Lippman SM
    Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
    Lancet Oncol. 2017;18:e457-e471.
    >> Share

  25. LEVIS BE, Binkley PF, Shapiro CL
    Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Lancet Oncol. 2017;18:e445-e456.
    >> Share

    July 2017
  26. DERKS MGM, Blok EJ, Seynaeve C, Nortier JWR, et al
    Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Jul 18. pii: S1470-2045(17)30419.
    >> Share

  27. MATHEW A, Brufsky A
    TACT2: improving treatment tolerability in early breast cancer.
    Lancet Oncol. 2017;18:843-845.
    >> Share

    June 2017
  28. DAS M
    Adjuvant pertuzumab improves early breast cancer outcomes.
    Lancet Oncol. 2017 Jun 15. pii: S1470-2045(17)30481.
    >> Share

  29. DAS M
    Olaparib provides benefit in metastatic breast cancer.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30453.
    >> Share

  30. BURKI TK
    Adjuvant capecitabine for HER2-negative breast cancer.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30451.
    >> Share

  31. CAMERON D, Morden JP, Canney P, Velikova G, et al
    Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, co
    Lancet Oncol. 2017 Jun 6. pii: S1470-2045(17)30404.
    >> Share

  32. STEBBING J, Baranau Y, Baryash V, Manikhas A, et al
    CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
    Lancet Oncol. 2017 Jun 2. pii: S1470-2045(17)30434.
    >> Share

    May 2017
  33. CHOPRA N, Turner NC
    Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.
    Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30430.
    >> Share

  34. BASELGA J, Im SA, Iwata H, Cortes J, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30376.
    >> Share

  35. KROP IE, Kim SB, Martin AG, LoRusso PM, et al
    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30313.
    >> Share

  36. MONTEMURRO F
    Trastuzumab emtansine in HER2-positive metastatic breast cancer.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30303.
    >> Share

  37. DIERAS V, Miles D, Verma S, Pegram M, et al
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30312.
    >> Share

  38. ALLGOOD PC, Maroni R, Hudson S, Offman J, et al
    Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
    Lancet Oncol. 2017 May 15. pii: S1470-2045(17)30340.
    >> Share

  39. GOURD E
    Switch to exemestane effective in early breast cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30341.
    >> Share

  40. EARL HM, Hiller L, Howard HC, Dunn JA, et al
    Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 May 4. pii: S1470-2045(17)30319.
    >> Share

    April 2017
  41. FOUAD TM, Barrera AM, Reuben JM, Lucci A, et al
    Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.
    Lancet Oncol. 2017;18:e228-e232.
    >> Share

    March 2017
  42. BURKI TK
    Sacituzumab govitecan activity in advanced breast cancer.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30232.
    >> Share

  43. RUGO HS, Seneviratne L, Beck JT, Glaspy JA, et al
    Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Lancet Oncol. 2017 Mar 14. pii: S1470-2045(17)30109.
    >> Share

    February 2017
  44. MAYOR S
    Service review: improving breast cancer care in Tanzania.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30160.
    >> Share

  45. MATHEW A, Brufsky A
    Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30150.
    >> Share

  46. BROWER V
    Scalp cooling and hair loss during breast cancer chemotherapy.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30158.
    >> Share

  47. LLOMBART-CUSSAC A, Cortes J, Pare L, Galvan P, et al
    HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30021.
    >> Share

  48. ZHANG P, Sun T, Zhang Q, Yuan Z, et al
    Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Lancet Oncol. 2017 Feb 10. pii: S1470-2045(17)30088.
    >> Share

  49. BROWER V
    Letrozole not superior to anastrozole for early breast cancer.
    Lancet Oncol. 2017 Feb 2. pii: S1470-2045(17)30081.
    >> Share

  50. POLGAR C, Ott OJ, Hildebrandt G, Kauer-Dorner D, et al
    Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year r
    Lancet Oncol. 2017;18:259-268.
    >> Share

  51. DIKMANS RE, Negenborn VL, Bouman MB, Winters HA, et al
    Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial.
    Lancet Oncol. 2017;18:251-258.
    >> Share

    January 2017
  52. LUEN SJ, Salgado R, Fox S, Savas P, et al
    Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Lancet Oncol. 2017;18:52-62.
    >> Share

    December 2016
  53. TANDAY S
    Duloxetine lessens joint pain in early-stage breast cancer.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30656.
    >> Share

  54. GOURD K
    San Antonio Breast Cancer Symposium 2016.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30658.
    >> Share

  55. BURKI TK
    Incidence of breast cancer in women with type 2 diabetes.
    Lancet Oncol. 2016;17:e523.
    >> Share

    November 2016
  56. BURKI TK
    Palbociclib improves survival in advanced breast cancer.
    Lancet Oncol. 2016 Nov 24. pii: S1470-2045(16)30619.
    >> Share

  57. VENKATESAN P
    Trastuzumab emtansine for HER2-positive breast cancer.
    Lancet Oncol. 2016 Nov 17. pii: S1470-2045(16)30589.
    >> Share

    October 2016
  58. BURKI TK
    Ribociclib in HR-positive, HER2-negative breast cancer.
    Lancet Oncol. 2016 Oct 13. pii: S1470-2045(16)30502.
    >> Share

  59. JATOI I, Benson JR, Toi M
    De-escalation of axillary surgery in early breast cancer.
    Lancet Oncol. 2016;17:e430-e441.
    >> Share

    September 2016
  60. ASDOURIAN MS, Skolny MN, Brunelle C, Seward CE, et al
    Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis.
    Lancet Oncol. 2016;17:e392-405.
    >> Share

    August 2016
  61. BALAKRISHNAN VS
    Physical exercise might affect breast cancer outcomes.
    Lancet Oncol. 2016 Aug 11. pii: S1470-2045(16)30389.
    >> Share

  62. BRUFSKY A
    Is there room for bevacizumab in metastatic breast cancer?
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30295.
    >> Share

  63. ZIELINSKI C, Lang I, Inbar M, Kahan Z, et al
    Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30154.
    >> Share

    July 2016
  64. TANDAY S
    IVF treatment not linked to breast cancer.
    Lancet Oncol. 2016 Jul 21. pii: S1470-2045(16)30371.
    >> Share

  65. BAKER H
    Adaptive treatments show promise in breast cancer.
    Lancet Oncol. 2016 Jul 14. pii: S1470-2045(16)30315.
    >> Share

  66. GHISLAIN I, Zikos E, Coens C, Quinten C, et al
    Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.
    Lancet Oncol. 2016;17:e294-304.
    >> Share

    June 2016
  67. BERNARDI D, Macaskill P, Pellegrini M, Valentini M, et al
    Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.
    Lancet Oncol. 2016 Jun 23. pii: S1470-2045(16)30101.
    >> Share

  68. VAN MAAREN MC, de Munck L, de Bock GH, Jobsen JJ, et al
    10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.
    Lancet Oncol. 2016 Jun 22. pii: S1470-2045(16)30067.
    >> Share

  69. BERTUCCI F, Viens P, Birnbaum D
    SPAG5: the ultimate marker of proliferation in early breast cancer?
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30092.
    >> Share

  70. ABDEL-FATAH TM, Agarwal D, Liu DX, Russell R, et al
    SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)00174.
    >> Share

    May 2016
  71. GIANNI L, Pienkowski T, Im YH, Tseng LM, et al
    5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Lancet Oncol. 2016 May 11. pii: S1470-2045(16)00163.
    >> Share

  72. BACHELOT T, Campone M, Tredan O
    PI3K targeting in breast cancer: the end of the beginning?
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00148.
    >> Share

  73. KROP IE, Mayer IA, Ganju V, Dickler M, et al
    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00106.
    >> Share

  74. CHAN A, Buyse M, Yao B
    Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.
    Lancet Oncol. 2016;17:e176-7.
    >> Share

  75. HASEGAWA T, Uno H, Wei LJ
    Neratinib after trastuzumab in patients with HER2-positive breast cancer.
    Lancet Oncol. 2016;17:e176.
    >> Share

    February 2016
  76. BURKI TK
    Happygram.
    Lancet Oncol. 2016;17:152.
    >> Share

  77. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    >> Share

    January 2016
  78. EVANS A
    Detection of DCIS and reduced invasive interval cancers.
    Lancet Oncol. 2016;17:14-5.
    >> Share

  79. BALAKRISHNAN VS
    Patient risk factors versus physician guidelines for anti-emetics.
    Lancet Oncol. 2016;17:e7.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016